The Lancet Haematology | Professor Yanmin Zhao, Professor He Huang, and Professor Jimin Shi: Moving Low-Dose Ruxolitinib Upfront to GVHD Prophylaxis Significantly Reduces the Risk of Acute GVHD After Haploidentical Transplantation

The Lancet Haematology | Professor Yanmin Zhao, Professor He Huang, and Professor Jimin Shi: Moving Low-Dose Ruxolitinib Upfront to GVHD Prophylaxis Significantly Reduces the Risk of Acute GVHD After Haploidentical Transplantation

Hematopoietic stem cell transplantation (HSCT) is an important treatment modality for various hematological malignancies. With the widespread application of haploidentical hematopoietic stem cell transplantation (Haplo-HSCT), limitations related to donor availability have been substantially overcome. However, graft-versus-host disease (GVHD), particularly clinically significant acute GVHD, remains an important complication affecting outcomes in transplant recipients. As an oral JAK1/2 inhibitor, ruxolitinib has demonstrated clear efficacy in the treatment of steroid-refractory GVHD, although long-term outcomes following salvage therapy remain an area for further improvement. Based on its ability to regulate inflammatory signaling and T-cell activation, ruxolitinib has increasingly been investigated for early GVHD prophylaxis in recent years. However, previous evidence has mainly come from exploratory studies, with prospective randomized controlled evidence remaining limited.
Prof. Cai Zhen: Challenges and Advances in the Treatment of Extramedullary Disease in Multiple Myeloma | 2026 Cross-Strait Hematology Conference

Prof. Cai Zhen: Challenges and Advances in the Treatment of Extramedullary Disease in Multiple Myeloma | 2026 Cross-Strait Hematology Conference

Extramedullary disease (EMD), an aggressive manifestation of multiple myeloma, presents longstanding challenges in clinical management, including substantial biological heterogeneity, difficulties in diagnosis and response assessment, resistance to conventional therapies, and a lack of high-level evidence from clinical trials. During the 2026 Cross-Strait Hematology Conference, Prof. Cai Zhen of the First Affiliated Hospital of Zhejiang University School of Medicine spoke with Oncology Frontier – Hematology Frontier about the key challenges of EMD, including target antigen escape, an immunosuppressive microenvironment, and difficulties in imaging-based response assessment. He also reviewed the latest advances and evolving treatment strategies involving bispecific antibodies, CAR-T-cell therapy, and novel antibody-drug conjugates (ADCs), providing authoritative and cutting-edge clinical insights into improving outcomes for patients with this high-risk disease subtype.
Prof. Wang Liang: How to Precisely Choose Between Autologous and Allogeneic Transplantation for First-Line Consolidation in Peripheral T-Cell Lymphoma? | 2026 Cross-Strait Hematology Conference

Prof. Wang Liang: How to Precisely Choose Between Autologous and Allogeneic Transplantation for First-Line Consolidation in Peripheral T-Cell Lymphoma? | 2026 Cross-Strait Hematology Conference

Peripheral T-cell lymphoma (PTCL) is highly heterogeneous and associated with poor prognosis, making the selection of an optimal first-line consolidation strategy a persistent clinical challenge. How can clinicians pursue deeper remission while balancing the graft-versus-lymphoma effect against the risk of non-relapse mortality? This lies at the heart of the clinical decision between autologous and allogeneic hematopoietic stem cell transplantation. During the 2026 Cross-Strait Hematology Conference, Prof. Wang Liang from Beijing Tongren Hospital, Capital Medical University, spoke with Oncology Frontier – Hematology Frontier about the positioning and selection of autologous versus allogeneic transplantation for first-line consolidation in PTCL based on evidence from evidence-based medicine. He also discussed prospectively how cellular immunotherapy may reshape future treatment paradigms.
Professor Huang He: Advances in Novel Cellular Immunotherapy and Clinical Translation丨2026 Cross-Strait Hematology Academic Conference

Professor Huang He: Advances in Novel Cellular Immunotherapy and Clinical Translation丨2026 Cross-Strait Hematology Academic Conference

Cellular immunotherapies such as CAR-T therapy are rapidly evolving, progressing from single-target and dual-target approaches to armored CAR-T cells, in vivo CARs, and other next-generation technologies that continue to overcome the limitations of conventional therapies. The 2026 Cross-Strait Hematology Academic Conference was held in Zhuhai, Guangdong, on August 21–22. During the conference, Oncology Frontier – Hematology Frontier interviewed Professor Huang He from the First Affiliated Hospital of Zhejiang University School of Medicine for an in-depth discussion on advances in novel cellular immunotherapies and their clinical translation. Drawing on his team's original research, Professor Huang systematically discussed key strategies for enhancing CAR-T cytotoxicity, overcoming the bottlenecks of universal manufacturing, and reducing treatment costs, providing a clear roadmap for translating next-generation cellular therapies into clinical practice.
CACA GU丨Yiping Zhu: Advancing Standardized, Whole-Course Bladder Cancer Management—from First-Line Treatment Innovation to Multidisciplinary Collaboration

CACA GU丨Yiping Zhu: Advancing Standardized, Whole-Course Bladder Cancer Management—from First-Line Treatment Innovation to Multidisciplinary Collaboration

The 2026 Pujiang Urologic Oncology Academic Conference was held in Shanghai. In recent years, the rapid development of antibody-drug conjugates (ADCs) and immunotherapy has reshaped the first-line treatment landscape for locally advanced or metastatic urothelial carcinoma (LA/mUC), while closer coordination among systemic therapy, surgery, and long-term follow-up has become increasingly important. Although emerging evidence has provided patients with more treatment options, challenges remain in pretreatment assessment, adverse event management, response evaluation, and long-term follow-up, with the ultimate goal of translating advances from clinical research into sustained real-world benefits. During the conference, Oncology Frontier · UroStream invited Professor Yiping Zhu from Fudan University Shanghai Cancer Center to share his perspectives on first-line treatment innovation, perioperative systemic therapy, the evolving role of surgery, and advances in molecular monitoring.
2026 Pujiang Urological Oncology Academic Conference丨Yijun Shen: ADCs Are Driving Bladder-Preservation Strategies Toward Precision Combination Therapy—from Combination Treatment in High-Risk NMIBC and MIBC Pathway Reshaping to Molecular Biomarker Stratification

2026 Pujiang Urological Oncology Academic Conference丨Yijun Shen: ADCs Are Driving Bladder-Preservation Strategies Toward Precision Combination Therapy—from Combination Treatment in High-Risk NMIBC and MIBC Pathway Reshaping to Molecular Biomarker Stratification

The rapid development of antibody-drug conjugates (ADCs) and immunotherapy is driving bladder-preservation strategies beyond single-modality local treatment toward an integrated approach combining systemic therapy, local treatment, and molecular stratification. Oncology Frontier – UroStream invited Professor Yijun Shen of Fudan University Shanghai Cancer Center to discuss combination bladder-preservation strategies for high-risk non-muscle-invasive bladder cancer (NMIBC), the implications of perioperative studies in muscle-invasive bladder cancer (MIBC) for traditional treatment pathways, and the potential applications of biomarkers such as circulating tumor DNA (ctDNA) and urinary tumor DNA (utDNA).
2026 Pujiang Urological Oncology Academic Conference丨Professor Guohai Shi: From Combination Therapy to Whole-Course Management, Advancing Long-Term Benefit in Advanced Renal Cell Carcinoma

2026 Pujiang Urological Oncology Academic Conference丨Professor Guohai Shi: From Combination Therapy to Whole-Course Management, Advancing Long-Term Benefit in Advanced Renal Cell Carcinoma

The 2026 Pujiang Urological Oncology Academic Conference was held in Shanghai. With the deeper integration of targeted therapy and immunotherapy, survival outcomes for advanced renal cell carcinoma (RCC) continue to improve. Clinical attention has also shifted from “whether to combine treatments” toward “how to select the optimal combination, how to sequence subsequent therapies, and how to balance efficacy with safety.” Oncology Frontier – Urology Frontier invited Professor Guohai Shi of Fudan University Shanghai Cancer Center for an exclusive interview. Professor Shi shared his clinical perspectives on long-term benefit, first-line treatment selection, decision-making after disease progression, and whole-course management in the real-world setting.
CACA GU丨Professor Xin Yao: Advancing Full-Course Urological Cancer Management Through Precision, Refinement, and Continuous Excellence

CACA GU丨Professor Xin Yao: Advancing Full-Course Urological Cancer Management Through Precision, Refinement, and Continuous Excellence

The diagnosis and treatment of urological cancers are currently undergoing a period of rapid evolution, driven by simultaneous advances in drug innovation and surgical techniques. Treatment strategies for urothelial carcinoma in the first-line and perioperative settings are evolving rapidly, while surgery for complex renal tumors is shifting from a focus on short-term safety toward greater emphasis on long-term renal function preservation. Against this backdrop, Oncology Frontier · UroStream invited Professor Xin Yao of Tianjin Medical University Cancer Institute and Hospital for an interview. He discussed the evolving treatment landscape of urothelial carcinoma, the priorities of the CACA Urological Oncology Committee, the “five-win” quality-control concept for partial nephrectomy, and future directions for the field.
Joe M. O’Sullivan Professor: APCCC 2026 Updates and Insights — Controversies in Hormonal Therapy Sequencing and Combination Strategies, the Prospects of Radioligand Therapy, and Global Equity in Prostate Cancer Care

Joe M. O’Sullivan Professor: APCCC 2026 Updates and Insights — Controversies in Hormonal Therapy Sequencing and Combination Strategies, the Prospects of Radioligand Therapy, and Global Equity in Prostate Cancer Care

In 2026, the Advanced Prostate Cancer Consensus Conference (APCCC), one of the most influential international expert consensus meetings in advanced prostate cancer, brought together experts from around the world to discuss systemic treatment strategies, risk-adapted treatment decisions, and emerging combination therapies, providing important guidance for clinical practice worldwide.
2026 Pujiang Urological Oncology Academic Conference丨Professor Hailiang Zhang: From Mechanisms of Immunotherapy Resistance to Precision Risk Stratification and Treatment—New Insights from the “Eggshell Structure” Discovered Through Spatial Multi-Omics and Advances in Systemic Therapy for Urological Tumors

2026 Pujiang Urological Oncology Academic Conference丨Professor Hailiang Zhang: From Mechanisms of Immunotherapy Resistance to Precision Risk Stratification and Treatment—New Insights from the “Eggshell Structure” Discovered Through Spatial Multi-Omics and Advances in Systemic Therapy for Urological Tumors

Systemic therapy for urological tumors is undergoing a profound transformation, shifting from empiric treatment toward mechanism-driven, precision-based risk stratification and whole-course management. In clear cell renal cell carcinoma (ccRCC), the immune-excluded tumor microenvironment is an important factor influencing the efficacy of immune checkpoint inhibitors. In urothelial carcinoma, antibody-drug conjugates (ADCs) combined with immunotherapy are moving beyond first-line treatment for advanced disease and increasingly being explored in the perioperative setting. For von Hippel-Lindau (VHL) syndrome, standardized management of this rare disease and the application of HIF-2α inhibitors are also reshaping traditional approaches to multi-organ intervention. As new mechanisms and therapeutic strategies continue to expand the boundaries of treatment, identifying patients most likely to benefit, dynamically evaluating treatment response, and appropriately transitioning patients with disease progression to subsequent therapies have become key questions in clinical practice. At the 2026 Pujiang Urological Oncology Academic Conference, Oncology Frontier – Urology Frontier invited Professor Hailiang Zhang of Huadong Hospital Affiliated to Fudan University for an exclusive interview. Professor Zhang discussed the mechanisms of immunotherapy resistance in renal cell carcinoma, advances in the diagnosis and treatment of urothelial carcinoma and VHL syndrome, as well as precision treatment selection and whole-course management.